We would like to thank our exhibitors for sponsoring this meeting, which includes pharmaceutical companies including AstraZeneca UK. They have had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the sponsored symposia presentations.
| Tuesday, May 12, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9:20 AM - 10:15 AM | Chair’s opening remarks followed by: Pulmonary hypertension: Early recognition and specialist referral pathways
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10:25 AM - 11:10 AM | Sponsored session to be confirmed This is a promotional symposium sponsored and organised by AstraZeneca and is intended for UK HCPs only.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:20 AM - 12:05 PM | Sponsored session to be confirmed This is a promotional symposium sponsored and organised by AstraZeneca and is intended for UK HCPs only.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 12:15 PM - 1:00 PM | Advanced lung cancer pathways: Delivering precision medicine at scale
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1:10 PM - 1:55 PM | Cystic fibrosis in the era of CFTR modulators: New challenges for adult services
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2:05 PM - 2:50 PM | The changing face of Tuberculosis: From reactivation to MDR-TB
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 3:00 PM - 3:45 PM | Sleep-disordered breathing beyond simple OSA: Managing complex ventilatory failure
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

4 CPD hours
SPEAKERS
Zaheer MangeraLung Cancer Lead, North Middlesex University Hospital, Royal Free London NHS Foundation Trust
Ari ManuelConsultant in Sleep and Respiratory Medicine, Nuffield Health Hereford Hospital, Senior Honorary Lecturer
Jessica PotterConsultant in Respiratory Medicine, North Middlesex University Hospital, Royal Free NHS Trust, Department of Respiratory Medicine, UCL




